# Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.

> **NCT01990885** · PHASE1,PHASE2 · COMPLETED · sponsor: **BioLineRx, Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Celiac Disease

## Interventions

- **DRUG:** BL-7010
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01990885
- **Lead sponsor:** BioLineRx, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01990885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01990885, "Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01990885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*